A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy - MK-7684A-002

Merck Sharp & Dohme LLC0 个研究点目标入组 255 人开始时间: 2022年12月23日最近更新: 2024年8月21日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Merck Sharp & Dohme LLC
入组人数: 255

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Has a histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC), Female participants must be not pregnant, not breastfeeding, and not be a woman of child-bearing potential (WOCBP). A WOCBP is eligible is she agrees to either use contraception, or be abstinent from heterosexual intercourse during the intervention period and for =120 days after the last dose of study intervention. If a WOCBP is randomized to docetaxel, she agrees not to donate eggs and either uses contraception or be abstinent from heterosexual intercourse during the treatment period and for =180 days after the last dose of docetaxel, Has adequate organ function, Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or reactive oxygen species (ROS) 1 directed therapy is not indicated as primary therapy, Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment, Has PD as determined by the investigator after platinum doublet chemotherapy for metastatic disease, Has measurable disease defined as at least 1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI), based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), Has provided tumor tissue for PD-L1 biomarker analysis from an archival sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated, Has a life expectancy of at least 3 months, Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 assessed within 7 days prior to randomization, Male participants randomized to docetaxel are eligible to participant if they agree to refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse; or 2) must agree to follow contraceptive guidance as per study protocol unless confirmed to be azoospermic during the intervention period and for at least 180 days after the last dose of docetaxel

排除标准

•Has known active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis, Has interstitial lung disease, or history of pneumonitis requiring steroids for treatment, Has known history of active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C, Has had an allogenic tissue/solid organ transplant, Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study, Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy, Has received docetaxel as monotherapy or in combination with other therapies, Has received previous treatment with another agent targeting the T-cell immunoreceptor with immunoglobulin [Ig] and immunoreceptor tyrosine-based inhibitory motif [ITIM] domains (TIGIT) pathway, Has received radiotherapy within 2 weeks of start of study intervention. One week washout is permitted for palliative radiation to non-CNS disease, Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention, Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention, Has severe hypersensitivity (=Grade 3) to docetaxel or pembrolizumab/vibostolimab coformulation and/or any of its excipients. Has an active autoimmune disease that has required systemic treatment in past 2 years, Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention

研究者

发起方

Merck Sharp & Dohme LLC

相似试验

进行中（未招募）

1 期

MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non-small cell lung cancer (NSCLC) compared to docetaxel aloneon Small Cell Lung cancerMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-004034-38-DKMerck Sharp & Dohme LLC240

进行中（未招募）

1 期

EUCTR2020-004034-38-FIMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc240

进行中（未招募）

1 期

MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non-small cell lung cancer (NSCLC) compared to docetaxel alone

EUCTR2020-004034-38-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.240

进行中（未招募）

1 期

EUCTR2020-004034-38-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc240

进行中（未招募）

1 期

EUCTR2020-004034-38-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc240